These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33973923)

  • 1. Therapy Dose Mediates the Relationship Between Buprenorphine/Naloxone and Opioid Treatment Outcomes in Youth Receiving Medication for Opioid Use Disorder Treatment.
    Hammond CJ; Kady A; Park G; Vidal C; Wenzel K; Fishman M
    J Addict Med; 2022 Mar-Apr 01; 16(2):e97-e104. PubMed ID: 33973923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex-based differences in psychiatric symptoms and opioid abstinence during buprenorphine/naloxone treatment in adolescents with opioid use disorders.
    Hammond CJ; Park G; Kady A; Rathod K; Rahman N; Vidal C; Wenzel K; Fishman M
    J Subst Abuse Treat; 2022 Feb; 133():108495. PubMed ID: 34218992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth.
    Subramaniam GA; Warden D; Minhajuddin A; Fishman MJ; Stitzer ML; Adinoff B; Trivedi M; Weiss R; Potter J; Poole SA; Woody GE
    J Am Acad Child Adolesc Psychiatry; 2011 Nov; 50(11):1120-8. PubMed ID: 22024000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth.
    Warden D; Subramaniam GA; Carmody T; Woody GE; Minhajuddin A; Poole SA; Potter J; Fishman M; Bogenschutz M; Patkar A; Trivedi MH
    Addict Behav; 2012 Sep; 37(9):1046-53. PubMed ID: 22626890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcomes among a cohort of African American buprenorphine patients: Follow-up at 12 months.
    Monico LB; Gryczynski J; Schwartz RP; Jaffe JH; O'Grady KE; Mitchell SG
    Am J Drug Alcohol Abuse; 2018; 44(6):604-610. PubMed ID: 29718715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harm Reduction Approach to Increasing Self-reported Safe Medication Storage Among Pregnant and Parenting People Receiving Opioid Use Disorder Treatment.
    Grist E; Thakkar B; Dacha P; Lutins E; Maxwell M; Martin CE
    J Addict Med; 2023 Mar-Apr 01; 17(2):215-218. PubMed ID: 36730907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.
    Woody GE; Poole SA; Subramaniam G; Dugosh K; Bogenschutz M; Abbott P; Patkar A; Publicker M; McCain K; Potter JS; Forman R; Vetter V; McNicholas L; Blaine J; Lynch KG; Fudala P
    JAMA; 2008 Nov; 300(17):2003-11. PubMed ID: 18984887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis.
    Mitchell MM; Schwartz RP; Choo TH; Pavlicova M; O'Grady KE; Gryczynski J; Stitzer ML; Nunes EV; Rotrosen J
    Drug Alcohol Depend; 2021 Feb; 219():108422. PubMed ID: 33352487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial.
    Polsky D; Glick HA; Yang J; Subramaniam GA; Poole SA; Woody GE
    Addiction; 2010 Sep; 105(9):1616-24. PubMed ID: 20626379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse.
    Rudolph KE; Shulman M; Fishman M; Díaz I; Rotrosen J; Nunes EV
    Addiction; 2022 Mar; 117(3):637-645. PubMed ID: 34338389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
    Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
    Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of Methadone and BUP/NX Dose Titration Patterns With Retention in Treatment and Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: Secondary Analysis of the OPTIMA Study.
    Bakouni H; Haquet L; Socias ME; Le Foll B; Lim R; Ahamad K; Jutras-Aswad D;
    J Addict Med; 2024 Mar-Apr 01; 18(2):167-173. PubMed ID: 38258865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder.
    Greenwald MK; Wiest KL; Haight BR; Laffont CM; Zhao Y
    Harm Reduct J; 2023 Dec; 20(1):173. PubMed ID: 38042801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study.
    Ling W; Nadipelli VR; Aldridge AP; Ronquest NA; Solem CT; Chilcoat H; Albright V; Johnson C; Learned SM; Mehra V; Heidbreder C
    J Addict Med; 2020; 14(5):e233-e240. PubMed ID: 32187112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder.
    Evans EA; Zhu Y; Yoo C; Huang D; Hser YI
    Addiction; 2019 Aug; 114(8):1396-1404. PubMed ID: 30916463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
    Hser YI; Zhu Y; Fei Z; Mooney LJ; Evans EA; Kelleghan A; Matthews A; Yoo C; Saxon AJ
    Addiction; 2022 Jan; 117(1):151-161. PubMed ID: 34105213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.